These endeavors resulted in inclusion of AEG-1 in MammaPrint early metastasis risk assessment assay (http://www.agendia.com/pages/mammaprint/21.php) which is the first and only FDA-approved individualized metastasis risk assessment assay for breast cancer that includes a unique 70-gene signature including AEG-1. This evidence concerns the gene MTDH and breast carcinoma.